Dianthus Therapeutics filed an 8-K, reporting that on March 10, 2026, they entered into an underwriting agreement to sell over 7.3 million shares of common stock at $81.00 each, expected to raise approximately $673.5 million. The offering is set to close on March 12, 2026.